IMMUNITYBIO, INC. (IBRX) Net margin 2016–2025
IMMUNITYBIO, INC. (IBRX) net profit margin by fiscal year — reported net income divided by reported revenue.
-310.3%FY2025 · since FY2016: -274565.9% → -310.3%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -310.3% | +2494.7 pp |
| FY2024 | -2805.0% | +91069.6 pp |
| FY2023 | -93874.6% | +80000.4 pp |
| FY2022 | -173875.0% | -136423.2 pp |
| FY2021 | -37451.8% | -782.2 pp |
| FY2020 | -36669.6% | -29504.4 pp |
| FY2019 | -7165.2% | +197571.0 pp |
| FY2018 | -204736.2% | +9537.2 pp |
| FY2017 | -214273.3% | +60292.6 pp |
| FY2016 | -274565.9% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice